AUG 10, 2026 · PHASE 2 TRIAL
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
ClinicalTrials.gov
Phase 2b dose-range finding trial with completed recruitment but no results posted; registry record only describes planned methods and endpoints, not outcomes.
Reported
Planned enrollment230
Primary efficacy endpointPercent change in body weight from Baseline…
Primary safety endpointsTEAEs, SAEs, AESI, laboratory abnormalities…